Role of p38 mitogen-activated protein kinase in middle ear mucosa hyperplasia during bacterial otitis media.
Hyperplasia of the middle ear mucosa contributes to the sequelae of acute otitis media. Understanding the signal transduction pathways that mediate hyperplasia could lead to the development of new therapeutic interventions for this disease and its sequelae. Endotoxin derived from bacteria involved in middle ear infection can contribute to the hyperplastic response. The p38 mitogen-activated protein kinase (MAPK) is known to be activated by endotoxin as well as cytokines and other inflammatory mediators that have been documented in otitis media. We assessed the activation of p38 in the middle ear mucosa of an in vivo rat bacterial otitis media model. Strong activity of p38 was observed 1 to 6 h after bacterial inoculation. Activity continued at a lower level for at least 7 days. The effects of p38 activation were assessed using an in vitro model of rat middle ear mucosal hyperplasia in which mucosal growth is stimulated by nontypeable Haemophilus influenzae during acute otitis media. Hyperplastic mucosal explants treated with the p38 alpha and p38 beta inhibitor SB203580 demonstrated significant inhibition of otitis media-stimulated mucosal growth. The results of this study suggest that intracellular signaling via p38 MAPK influences the hyperplastic response of the middle ear mucosa during bacterial otitis media.
Palacios
Sean D
SD
Department of Surgery/Otolaryngology, University of California-San Diego, La Jolla, 92037, USA.
Pak
Kwang
K
Rivkin
Alexander Z
AZ
Kayali
Ayse G
AG
Austen
Darrell
D
Aletsee
Christoph
C
Melhus
Asa
A
Webster
Nicholas J G
NJ
Ryan
Allen F
AF
D000208:Acute Disease; D000818:Animals; D004195:Disease Models, Animal; D004432:Ear, Middle / Q000473:pathology*; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006192:Haemophilus Infections / Q000382:microbiology / Q000473:pathology*; D006193:Haemophilus influenzae / Q000472:pathogenicity*; D006801:Humans; D006965:Hyperplasia; D007093:Imidazoles / Q000494:pharmacology; D008297:Male; D020928:Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism*; D009092:Mucous Membrane / Q000378:metabolism / Q000473:pathology; D010033:Otitis Media / Q000382:microbiology / Q000473:pathology*; D011725:Pyridines / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D048051:p38 Mitogen-Activated Protein Kinases
D004791:Enzyme Inhibitors; D007093:Imidazoles; D011725:Pyridines; D020928:Mitogen-Activated Protein Kinases; D048051:p38 Mitogen-Activated Protein Kinases; C093642:SB 203580